Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)

Inclusion Criteria: 1. Patients must have been \< 18 years of age when originally diagnosed. 2. Histologic Diagnosis: Patients must have histologic verification of LGG at original diagnosis. Exceptions are optic pathway gliomas in children with neurofibromatosis or children with large hypothalamic tumours for which a diagnostic biopsy does not seem necessary. Patients with disseminated low grade glioma are eligible. 1. Astrocytoma Variants: fibrillary, protoplasmic, gemistocytic, mixed 2. Pilocytic Astrocytoma 3. Pleomorphic Xanthoastrocytoma 4. Infantile desmoplastic astrocytoma 5. Ganglioglioma 6. Oligodendroglioma 7. Mixed glioma (including oligo-astrocytoma) 8. Pilomyxoid astrocytoma 3. Performance Level :Patients must have an ECOG performance status of 0, 1 or 2 or a Lansky/Karnofsky score \> 50 4. Life expectancy: Patients must have a life expectancy of \* 2 months. 5. Prior Therapy: Patients are eligible at the time of diagnosis or first progression following treatment with surgery only. 6. Measurable Disease: Patients must have measurable disease, documented by radiographic criteria. 7. Concomitant Medications 1. Steroids: Steroids may be used at the time of inclusion to control progressive symptoms. 2. Anti-epileptic medications are permitted - levetiracetam (Keppra) or clobazam (Frisium) being the preferred anti-epileptic medications for chronic use reserving phenytoin and lorazepam for acute seizure control. 8. Organ Function Requirements: All patients must have adequate organ and bone marrow function within 7 days of starting chemotherapy (ANC \* 1.0 x 109/L /, and platelet count \* 100 x 109/L (transfusion independent). 9. Regulatory: All patients and/or their parents or legal guardians must sign a written informed consent and all institutional requirements for human studies must be met. This study is open to all participants regardless of gender or ethnicity. Exclusion Criteria: Inclusion criteria are restrictive. Patient must meet all inclusion criteria.